TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome
Brief Summary: The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk for respiratory distress syndrome.


Options:
A: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
B: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
C: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
D: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Care Transitions Intervention
Brief Summary: This intervention tests whether encouraging older patients and their caregivers to assert a more active role in their care transitions could improve clinical outcomes. Patients are supported by a nurse transition coach and specific tools, including a Personal Health Record.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Patient video decision aid & telephone coaching | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Printed educational brochure | Intervention Type: BEHAVIORAL; Name: Patient video decision aid & telephone coaching; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Printed educational brochure; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Care Transitions Intervention; Assigned to Arm(s): N/A
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: Health coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients
Brief Summary: The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 4; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 5; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Bimekizumab dosing regimen 5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Placebo
B: Arm Label: HLX03 group; Type: EXPERIMENTAL; Interventions: Drug: HLX03 | Arm Label: adalimumab group; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: HLX03; Assigned to Arm(s): HLX03 group | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): adalimumab group
C: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
D: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients
Brief Summary: The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.


Options:
A: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
B: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
C: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients
Brief Summary: The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.


Options:
A: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
B: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metabolism and Bone Health
Brief Summary: Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.


Options:
A: Arm Label: Genistein vs. Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Arm Label: Genistein dose and source; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Intervention Type: DIETARY_SUPPLEMENT; Name: Genistein vs Risedronate; Assigned to Arm(s): Genistein dose and source, Genistein vs. Risedronate
B: Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): N/A
C: Arm Label: Alendronate 70 mg; Type: EXPERIMENTAL; Interventions: Drug: Alendronate, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Risendronate placebo | Arm Label: Risendronate 35 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate 35 mg, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Alendronate placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Risedronate 35 mg; Assigned to Arm(s): Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Elemental Calcium; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DRUG; Name: Risendronate placebo; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Alendronate placebo; Assigned to Arm(s): Risendronate 35 mg
D: Arm Label: 5 mg Before Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Drug: risedronate | Arm Label: 35 mg After Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Arm Label: 35 mg Before Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 5 mg Before Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg After Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg Before Breakfast

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Impact of a Bulletin Board on a Web-Based Smoking Cessation Intervention
Brief Summary: RATIONALE: Stop-smoking information on the smokefree.gov website may help people quit smoking and remain a nonsmoker.

PURPOSE: This clinical trial is studying how well the smokefree.gov website works with an electronic bulletin board in helping United States federal employees quit smoking.


Options:
A: Arm Label: San Francisco Internet Stop Smoking Site; Type: EXPERIMENTAL; Interventions: Behavioral: UCSF/SFGH Internet Stop Smoking Study site | Intervention Type: BEHAVIORAL; Name: UCSF/SFGH Internet Stop Smoking Study site; Assigned to Arm(s): San Francisco Internet Stop Smoking Site
B: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Processes in PTSD: Treatment
Brief Summary: This study will evaluate the effectiveness of cognitive processing therapy versus its individual components in treating women with post-traumatic stress disorder (PTSD) and depression brought on by sexual assault.


Options:
A: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
B: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Written Exposure; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy, Behavioral: Hypnosis | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Hypnosis; Assigned to Arm(s): 2
D: Arm Label: Imaginal Exposure First, then Alcohol Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure, Behavioral: Alcohol Skills Training | Arm Label: Alcohol Skills First, then Imaginal Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure, Behavioral: Alcohol Skills Training | Arm Label: Supportive Counseling/Telehealth; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Telehealth | Arm Label: Alcohol Skills First, no additional treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Alcohol Skills Training | Arm Label: Imaginal Exposure First, no additional treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure | Intervention Type: BEHAVIORAL; Name: Imaginal Exposure; Assigned to Arm(s): Alcohol Skills First, then Imaginal Exposure, Imaginal Exposure First, no additional treatment, Imaginal Exposure First, then Alcohol Skills | Intervention Type: BEHAVIORAL; Name: Alcohol Skills Training; Assigned to Arm(s): Alcohol Skills First, no additional treatment, Alcohol Skills First, then Imaginal Exposure, Imaginal Exposure First, then Alcohol Skills | Intervention Type: BEHAVIORAL; Name: Supportive Telehealth; Assigned to Arm(s): Supportive Counseling/Telehealth

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Processes in PTSD: Treatment
Brief Summary: This study will evaluate the effectiveness of cognitive processing therapy versus its individual components in treating women with post-traumatic stress disorder (PTSD) and depression brought on by sexual assault.


Options:
A: Arm Label: PE-HBT; Type: EXPERIMENTAL; Interventions: Behavioral: PE | Arm Label: PE-SD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PE | Intervention Type: BEHAVIORAL; Name: PE; Assigned to Arm(s): PE-HBT, PE-SD
B: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Written Exposure; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Treatment for Insomnia (CBT-I) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive Behavioral Treatment for Insomnia (CBT-I); Assigned to Arm(s): 1
D: Arm Label: PPRS video; Type: EXPERIMENTAL; Interventions: Behavioral: PPRS | Arm Label: PIRI video; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PIRI | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PPRS; Assigned to Arm(s): PPRS video | Intervention Type: BEHAVIORAL; Name: PIRI; Assigned to Arm(s): PIRI video

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Recombinant Human Thrombin (rhThrombin) and Thrombin-JMI (Bovine Thrombin) in Surgical Hemostasis
Brief Summary: The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin.


Options:
A: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
B: Arm Label: Clamp-Crush technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crush technique | Arm Label: Stapler hepatectomy; Type: EXPERIMENTAL; Interventions: Procedure: Stapler hepatectomy | Intervention Type: PROCEDURE; Name: Clamp-Crush technique; Assigned to Arm(s): Clamp-Crush technique | Intervention Type: PROCEDURE; Name: Stapler hepatectomy; Assigned to Arm(s): Stapler hepatectomy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rThrombin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: bovine thrombin | Intervention Type: BIOLOGICAL; Name: rThrombin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bovine thrombin; Assigned to Arm(s): 2
D: N/A

Answer: C